Remdesivir costs around Rs 5,000 per vial with a total treatment
cost in the range of Rs 35,000-50,000.
The Central
Drugs Standard Control Organisation (CDSCO) has approved five drugs in the
last month for Covid-19 treatment – two antiviral: Remdesivir and Favipiravir –
and three for easing the symptoms: Dexamethasone, Tocilizumab and Itolizumab.
These drugs’ use is bound to birth complications considering there are doubts
about the evidence the government has furnished – or not – to approve their
use.
Remdesivir
costs around Rs 5,000 per vial with a total treatment cost in the range of Rs
35,000-50,000. Favipiravir costs Rs 103 per 200 mg tablet; the total treatment
cost ranges from Rs 12,000 to Rs 15,000. A vial of Itolizumab costs around Rs
8,000 and the total treatment cost could be between Rs 32,000 and Rs 50,000.
Tocilizumab costs Rs 40,000 to Rs 50,000 per vial.
Remdesivir
Remdesivir was
approved for clinical use for both children and adults by the CDSCO as an
injection on June 1, amid controversies surrounding its efficacy. This drug is
manufactured by Gilead Sciences Inc. The first randomised double-blind study
showed no statistically significant treatment efficacy in severe Covid-19
patients. Gilead’s own study reported that no fewer people died when on the
drug. However, while the study also reported patients on Remdesivir recovered
four days earlier on average, independent experts aren’t convinced.
A press release by
the US National Institute of Arthritis and Infectious Disease (NIAID), the
study’s sponsor, nonetheless said hospitalised patients with Covid-19 recovered
faster when they were on Remdesivir compared to placebo. There was also a
controversy surrounding the changing of end points of the study, to get a
favourable outcome. Gilead’s quest to secure approval for the drug were also
shadowed by reports of lobbying to influence the FDA and other authorities.
